Delving into the Latest Updates on Ningbo Wenda Pharmaceutical Technology Co., Ltd with Synapse

Overview

Tags

Immune System Diseases

Other Diseases

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	3
Neoplasms	3
Endocrinology and Metabolic Disease	2
Nervous System Diseases	2
Hemic and Lymphatic Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6

Top 5 Target	Count

TYK2(Tyrosine-protein kinase 2)	2
BET(Bromodomain and extra terminal domain protein)	1

1) To evaluate the safety and tolerability of single and multiple oral administration of different doses of WD-890 tablets in healthy Chinese subjects; 2) To evaluate the pharmacokinetic and pharmacodynamic characteristics of single and multiple oral administration of different doses of WD-890 tablets in healthy Chinese subjects.

Start Date25 Nov 2023

Sponsor / Collaborator

Ningbo Wenda Pharmaceutical Technology Co., Ltd

100 Clinical Results associated with Ningbo Wenda Pharmaceutical Technology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Ningbo Wenda Pharmaceutical Technology Co., Ltd

Login to view more data

2

Literatures (Medical) associated with Ningbo Wenda Pharmaceutical Technology Co., Ltd

01 Jul 2017·Cancer Research

Abstract 1382: A novel BET family bromodomain inhibitor NHWD-870 represents a promising therapeutic agent for a broad spectrum of cancers

Author: Wang, Nenghui ; Yan, Qin ; Yin, Mingzhu

AbstractSmall molecule inhibitors of the bromodomain and extraterminal domain (BET) proteins have emerged as a promising option for cancer therapy. NHWD-870 is a potent and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2/3/4/T. NHWD-870 exhibited robust single agent activity in cell viability assay across cancer cell lines derived from solid tumors, leukemia and lymphomas. Further characterization of cancer cell responses to NHWD-870 indicated that NHWD-870 manifested diverse mechanisms of action in different cancer settings. These include: 1) inhibition of tumor cell growth by downregulating the PDGFRβ, MEK1/2 and STAT1/MYC signaling in tumor cells; 2) inhibition of tumor angiogenesis by decreasing PDGF production in tumor cells and the PDGFRβ and MEK1/2 signaling in endothelial cells. Consistent with its broad spectrum of activities in vitro, NHWD-870 has potent tumor suppressive efficacies in xenograft mouse models of small cell lung cancer, triple negative breast cancer and ovarian cancer. These results support its further development for diverse solid tumor indications in the clinic.Citation Format: Nenghui Wang, Mingzhu Yin, Qin Yan. A novel BET family bromodomain inhibitor NHWD-870 represents a promising therapeutic agent for a broad spectrum of cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1382. doi:10.1158/1538-7445.AM2017-1382

Nature CommunicationsQ1 · CROSS-FIELD

Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction

Q1 · CROSS-FIELD

ArticleOA

Author: Ye, Rui ; Cai, Wesley L ; Yan, Qin ; Li, Jiali ; Chen, Xiang ; Guo, Ying ; Yin, Mingzhu ; Wang, Nenghui ; Peng, Cong ; Yang, Qiaohong ; Pei, Shiyao ; Sun, Hongyin ; Li, Yao ; Hu, Rui ; Tao, Yongguang

AbstractSmall molecule inhibitor of the bromodomain and extraterminal domain (BET) family proteins is a promising option for cancer treatment. However, current BET inhibitors are limited by their potency or oral bioavailability. Here we report the discovery and characterization of NHWD-870, a BET inhibitor that is more potent than three major clinical stage BET inhibitors BMS-986158, OTX-015, and GSK-525762. NHWD-870 causes tumor shrinkage or significantly suppresses tumor growth in nine xenograft or syngeneic models. In addition to its ability to downregulate c-MYC and directly inhibit tumor cell proliferation, NHWD-870 blocks the proliferation of tumor associated macrophages (TAMs) through multiple mechanisms, partly by reducing the expression and secretion of macrophage colony-stimulating factor CSF1 by tumor cells. NHWD-870 inhibits CSF1 expression through suppressing BRD4 and its target HIF1α. Taken together, these results reveal a mechanism by which BRD4 inhibition suppresses tumor growth, and support further development of NHWD-870 to treat solid tumors.

100 Deals associated with Ningbo Wenda Pharmaceutical Technology Co., Ltd

Login to view more data

100 Translational Medicine associated with Ningbo Wenda Pharmaceutical Technology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 1 Clinical

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NHWD-870 ( BET )	NUT midline carcinoma More	Phase 2
WD-890 ( TYK2 )	Arthritis, Psoriatic More	Phase 1
WD-910 ( TYK2 )	Multiple Sclerosis More	Preclinical
WD-930	Neoplasms More	Preclinical
WD-920	Parkinson Disease More	Preclinical